Document is current
Any future updates will be listed below
-
Authors
Paradis, Victor
Kanou, Meghan
Paradis, Louis
Labrosse, Roxane
Samaan, Kathryn
Bégin, Philippe
Gingras-Lessard, Florence
Graham, François
Des Roches, Anne
- License Information
-
More Information
Article History
Received: 15 March 2026
Accepted: 12 May 2026
First Online: 2 June 2026
Declarations
Ethics approval and consent to participate: This retrospective chart review was approved by our local ethic committee.
Consent for publication: Not applicable.
Competing Interests: The authors declare no competing interests. The following authors have received grants in the past 36 months for other projects unrelated to this one: Dr. Philippe Bégin has received consulting fees and honoraria from ALK, Astra Zeneca, Sanofi, Bausch Health, Pfizer. He is also a clinical trial investigator with DBV Technologies (Viaskin Patch), Regeneron, Novartis, ALK, and Sanofi. He is on the Board of Directors of the CSACI, AAIQ and CAAIF and medical advisor to Food Allergy Canada.Dr Anne Des Roches has received consulting fees from ALK. She is also a clinical trial co-investigator with DBV Technologies (Viaskin Patch), Regeneron, Novartis, ALK, and Sanofi.Dr Roxane Labrosse has received honoraria from AstraZeneca Grifols and for educational activities unrelated to the current manuscript. The remaining authors have no conflicts of interest to declare.
